Agios Pharmaceuticals Inc... (AGIO)
34.02
0.70 (2.10%)
At close: Jan 15, 2025, 10:35 AM
Company Description
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology.
The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications.
Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Agios Pharmaceuticals Inc.
| Country | United States |
| IPO Date | Jul 24, 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 383 |
| CEO | Brian M. Goff M.B.A. |
Contact Details
Address: 88 Sidney Street Cambridge, Massachusetts United States | |
| Website | https://www.agios.com |
Stock Details
| Ticker Symbol | AGIO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001439222 |
| CUSIP Number | 00847X104 |
| ISIN Number | US00847X1046 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Brian M. Goff M.B.A. | Chief Executive Officer & Director |
| Cecilia Jones | Chief Financial Officer |
| James William Burns | Corporate Secretary & Chief Legal Officer |
| Dr. Craig B. Thompson M.D. | Founder |
| Dr. Lewis Clayton Cantley Ph.D. | Founder |
| Dr. Sarah Gheuens M.D., Ph.D. | Chief Medical Officer and Head of Research & Development |
| Dr. Shin-San Su Ph.D. | Founder |
| Dr. Tak Wah Mak D.Sc., FRSC, Ph.D. | Founder |
| T. J. Washburn | Vice President, Controller & Principal Accounting Officer |
| Tsveta Milanova | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 13, 2025 | 8-K | Current Report |
| Jan 07, 2025 | 4 | Filing |
| Jan 06, 2025 | 8-K | Current Report |
| Dec 13, 2024 | 4 | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 13, 2024 | 4 | Filing |
| Nov 12, 2024 | 4 | Filing |
| Nov 12, 2024 | 4 | Filing |
| Nov 08, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 31, 2024 | 10-Q | Quarterly Report |